Head and neck cancer in 2010: Maximizing survival and minimizing toxicity.
Nat Rev Clin Oncol., Feb;8(2):72-4 (2011)
Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors.
Bone Marrow Transplant., Apr;25(8):885-94 (2000)
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
J. Clin. Oncol., Jan;21(2):320-6 (2003)
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
Med. Oncol., 20(1):7-12 (2003)
Is patient travel distance associated with survival on phase II clinical trials in oncology?
J. Natl. Cancer Inst., Sep;95(18):1370-5 (2003)
Management of recurrent head and neck cancer: recent progress and future directions.
Drugs., Aug;71(12):1551-9 (2011)
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.
Clin. Cancer Res., Mar;10(6):1956-62 (2004)
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Clin. Cancer Res., Dec;11(23):8418-24 (2005)
Oncogenic osteomalacia as a harbinger of recurrent osteosarcoma.
Sarcoma., 3(2):95-9 (1999)
Outcomes of computerized physician order entry in an electronic health record after implementation in an outpatient oncology setting.
J Oncol Pract., Jul;7(4):233-7 (2011)
Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy.
J Hematother., Dec;5(6):617-24 (1996)
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Semin Radiat Oncol., Apr;9(2 Suppl 1):70-6 (1999)